Stocktoria
Caribou Biosciences, Inc. CRBU
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-07-23
Caribou Biosciences, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -1329.4% | -1667.2% | -336.6% | -768.2% | -697.8% |
| Net margin | -1327.4% | -1491.9% | -296.1% | -717.8% | -697.3% |
| FCF margin | -1006.8% | -1431.7% | -304.3% | -703.3% | -360.9% |
| Return on assets | -84.5% | -47.6% | -23.6% | -26.6% | -15.1% |
| Return on equity | -121.2% | -58.9% | -27.7% | -33.0% | -17.3% |
| Current ratio | 5.71 | 7.16 | 11.97 | 9.25 | 15.15 |
| Revenue growth | 11.7% | -71.0% | 148.9% | 44.3% | -22.4% |
Source: SEC EDGAR filings · CIK 0001619856 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.